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Abstract
Cancer initiating cells (CIC) are stem-like cells. CIC may contribute not only to the initiation of cancer but also to cancer
recurrence because of the resistance of CIC both to chemotherapy and radiation therapy. From the MCF-7 and MDA-MB231
breast cancer cell lines and primary culture of patient breast cancer cells, we isolated by flow cytometry a CIC subset of cells
with the CD44
+/CD24
2or low phenotype. The CD44
+/CD24
2or low subset showed increased sphere formation and resistance
to radiation compared to the non- CD44
+/CD24
2or low subset. The increased radiation resistance was not dependent on the
result of altered non-homologous end joining (NHEJ) DNA repair activity as both NHEJ activity and expression of the various
proteins involved in NHEJ were not significantly different between the CD44
+/CD24
2or low and non- CD44
+/CD24
2or low
subsets. However, activation of ATM signaling was significantly increased in CD44
+/CD24
2or low cells compared to non-
CD44
+/CD24
2or low cells in both from breast cancer cell lines and primary human breast cancer cells. Application of an ATM
inhibitor effectively decreased the radiation resistance of CD44
+/CD24
2or low subset, suggesting that targeting ATM
signaling may provide a new tool to eradicate stem-like CIC and abolish the radiation resistance of breast cancer.
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Introduction
The existence of stem-like cancer initiating cells (CIC) is a
hypothesis put forth both to explain the initiation of cancer and
the recurrence of cancer after treatment. Evidence supporting the
presence of CIC has been developed both in hematologic
malignancies and solid tumors. In breast cancer, a subset of
CD44
+/CD24
2/low/ESA+ cells has been identified with as few as
100 cells of these cells being able to form tumors in mice [1,2,3].
The CD44
+/CD24
2/low/ESA+ cells exhibit unlimited propaga-
tion and can give rise to subpopulations of tumorigenic and non-
tumorigenic cells. Therefore, the subset of CD44
+/CD24
2/low/
ESA+ has been recognized as being breast cancer initiating cells
(CIC). In breast cancers CD44
+/CD24
2/low cells are predomi-
nately limited to triple negative breast cancer, a subgroup of basal-
like tumors, and the presence of the CD44
+/CD24
2/low subset is
correlated inversely with breast cancer patient survival [4,5]. In
addition to breast cancer tissue, CD44
+/CD24
2/low/ESA+ cells
have also been isolated from breast cancer-derived cell lines with
several of such cell lines containing a subset of CD44
+/CD24
2/
low2/EAS+ cells possessing CIC properties such as the capacity for
self-renewal [1,6,7,8].
One of the characteristics of CIC, including CIC isolated from
breast cancer cell lines, is resistance to radiation and chemother-
apy which may adversely impact cancer treatment although the
mechanisms responsible for the resistance are still poorly
understood [9,10,11,12]. The growth of the breast cancer cell
lines MCF-7 and MDA-MB-231 as mammospheres has demon-
strated the enrichment in the mammospheres of CD44
+/CD24
2/
low2/EAS+ cells and the cells in the mammospheres are more
radiation resistance than cells grown in monolayer [13]. The
radiation resistance of CIC has also been demonstrated in mouse
mammary progenitor cells with an increase of progenitor cells with
the characteristic stem cell surface markers following radiation of
primary BALB/c mouse mammary epithelial cells [11]. Fractional
radiation also increased the CD44
+/CD24
2/low2 subset in breast
cancer cell lines [14]. However, due to the dynamic features of
CIC, that is the need to both self-renew and to differentiate, it is
unknown if the CD44/CD24 surface phenotype of CIC is directly
responsible for the observed radiation resistance.
The mechanisms underlying the relative resistance of CIC to
radiation and chemotherapy are important to overcoming the
barriers resistance poses to more effective cancer treatment. Recent
data with CIC isolated from human breast cancer cells and mouse
mammarytumorcellsimplicate lowlevelsofreactive oxygen species
(ROS) and decreased levels of cellular defenses against oxidative
stress in CIC as contributing to radiation resistance [13,15]. In
addition, enhanced DNA damage repair activity could also
contribute to radiation resistance of CIC. After radiation, increased
activation of Ataxia-Telangiectasia Mutated (ATM) kinase pathway
has been reported in glioma stem cells andCD133-positive atypical
teratoid/rhabdoid tumor cells [16,17]. Analysis of the survival
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shoulder region’’ suggestive of a difference in DNA repair between
CIC and non-CIC. Therefore, targeting the differential capacity for
DNA repair in CIC suggests a mechanism for obtaining enhanced
therapeutic efficacy of radiation. In this study, we demonstrate that
CIC isolated as a CD44
+/CD24
2/low/ESA+ subset of cells from
both human breast cancer cell lines and primary culture of breast
cells isolated from patients with fibroadenoma (patient A) and
invasive ductal carcinoma (patient B) were more radioresistant than
control subsets and that the radiation resistance cohort was
characterized by the presence of stem cells surface markers. The
radiation resistance of the human breast CIC was markedly
decreased by targeting the ATM with the inhibitor KU55933.
Results
1. Post-radiation survival analysis of CD44+/CD242/or
low (MCF-7, MDA-MB231, and patient’s cells) vs CD442/
CD24 high (MCF-7 and patient’s cells) or CD44+/CD24+
(MDA-MB-231
In previous studies, breast cancer cells cultured as mammo-
spheres in serum-free medium are recognized as a CIC enriched
subset and show enhanced radiation resistance and increased
percentage of CD44
+/CD24
2or low cells [13,18]. According to the
previous studies, we assume that the CD44
+/CD24
2or low cells
could be CIC enriched subset in our study and this subset is
directly responsible for enhanced radiation resistance. To test this
assumption, we isolated CD326(ESA)
+/CD44
+/CD24
2or low cells
not only from the breast cancer cell lines MCF7 and MDA-
MB231 but also from primary cultures of human breast tumor
cells. CD326 positive cells constituted 99% of MCF7 cells, 70% of
MDA-MB231 cells, 73% of primary cells from patient A, and 95%
of cells from patient B (Figure S1A–D, left panels). The CD326
subset was then examined for the presence of CD44 and CD24.
The CD44
+/CD24
2or low subset constituted 0.1% of the MCF-7
cells and 86% of the MDA-MB-231 cells (Figure S1 A and S1 B,
right panels). In patients A and B, the CD44
+/CD24
2or low subset
of cells was 7.4% and 0.1%, respectively (Figure S1 C and S1 D,
right panels). The greatest portion of a CD44
+/CD24
2 subset was
found in the mesenchyme-like breast cancer cell line MDA-MB-
231 as described before [8,19,20] and this cell line has previously
been characterized as having a basal cell phenotype [21].
We first examined radiation sensitivity of the various CD44/
CD24 subsets in MCF and MDA-MB-231 cells by assaying post-
radiation clonogenic survival. A significant resistance to radiation
(P,0.01) was seen in the CD44
+/CD24
2or low subsets of cells from
MCF-7and MDA-MB-231 cells compared to that of CD44
+/
CD24
high subset in MDA-MB-231, CD44
2/CD24
high subset in
MCF-7 or unsorted cell populations (Figure 1A and 1B). To verify
results from the breast cancer cell lines, we performed similar
studies on isolated CD44
+/CD24
2or low subsets from primary
culture of benign breast tumor (patient A) and an invasive breast
cancer cells (patient B). First, we examined the stem-like property
of isolated cells by sphere formation assay. By 12 days after the
culture in serum-free medium, the CD44
+/CD24
2or low subset
formed 62 and 69% more spheres than did CD44
2/CD24
high
subsets in patient A and B, respectively (Figure 1 C and 1D,
P,0.05). Radiation survival curves showed that the CD44
+/
CD24
2or low subsets from both patients were more resistant
compared to the CD44
2/CD24
high subsets (Figure 1E and 1F). At
2Gy the survival fractions of the CD44
+/CD24
2or low subset vs
CD44
2/CD24
high subset was 0.47 vs 0.27 in patient A (P,0.01)
and 0.43 vs 0.18 in patient B (P,0.01).
2. The radiation resistance of breast cancer cells is related
to CD44
+/CD24
2or low phenotype
The stem-like phenotype of CIC is a dynamic process in that the
CIC must undergo continued ‘‘differentiation’’ to form the bulk of
the cancer and self-renewal to maintain the capacity for continued
stemness or stem-like phenotype. We next examined if the sorted
CIC subset maintained their surface phenotype during subsequent
culture. In these experiments CD44/CD24 expression was
examined in the MCF-7 and MDA-MB-231 cells, sorting these
cell lines into CD44
+/CD24
2/low and CD44
2/CD24
high subsets
for the MCF-7 cell line and CD44
+/CD24
2 and CD44
+/CD24
+
subsets for the MDA-MB-231 cell line. After 7 days of culture both
the MCF7 and MDA-MB-231 subsets as well as the unsorted
parent cells retained their original CD44/CD24 phenotypes (data
not shown). However, after 20 days of culture the CD44
+/
CD24
2/low MCF7 subset had changed phenotype with 69.4% of
the cells now CD44
2 and in the CD44
2/CD24
high subset 5.8% of
the cells were now CD44
+ (Figure 2, upper panel). In the MDA-
MB-231 cells similar phenotype changes were also observed after
20 days (Figure 2, lower panel) with 77.7% of the cells in the
CD44+/CD24+ subset becoming CD242 and 3.5% of CD242
cells in CD44+/CD242 subset becoming CD24+. It seems that
the stem-like cell phenotype could switch to a non stem-like cell
phenotype and vice versa.
To verify further a relationship between the CD44
+/CD24
2or
low phenotype and radiation resistance, we compared the
clonogenic survival of MCF-7 and MDA-MB-231 subsets to
radiation after culture for 7 days and 2 weeks for MCF-7 or 3
weeks for MDA-MB-231. These experiments took advantage of
the surface phenotype of the sorted cell subsets being maintained
for 7 days but not 20 days of culture. Indeed, the clonogenic
survival fraction at 2Gy of radiation was significantly greater in the
seven day-culture of the MCF7 CD44
+/CD24
2or low subset
compared to that of CD44
2/CD24
high subset (Figure 3A) but by
two weeks of culture the radiation resistance of the CD44
+/
CD24
2or low subset was no longer significantly different than the
CD44
2/CD24
hgh subset (Figure 3B). Similarly, with the MDA-
MB-231 subsets the increased survival fraction of the CD44
+/
CD24
2 subset compared to the CD44
+/CD24
+ subset after 7 days
of culture disappeared in the 20-day cultures (Figure 3C and 3D).
We then resorted the MCF7 and MDA-MB-231 subsets after 20
days in culture into CIC and non CIC subsets and examined by
clonogenic assays the radiation survival among the 20 day cultured
subsets and re-sorted subsets (Figure 4). In both the MCF7 and
MDA-MB-231 cell lines, the resorted CIC subsets are significantly
radiation resistant (P,0.01) whether sorted from the original CIC
subsets or not, indicating that CD44
+/CD24
2/low phenotype
determine the radiation resistance of the cells.
3. Analysis of end-joining of double-strand DNA breaks in
CD44
+/CD24
2or low vs. CD44
2/CD24
high (MCF-7 and
HCC1937) or CD44+/CD24+ (MDA-MB-231)
subpopulations
DNA repair via non-homologous end joining (NHEJ) is one of
the immediate responses of cells to radiation-induced DNA
damage. To address if the enhanced radiation resistance of
CD44
+/CD24
2or low subsets was due to increased DNA repair
activity, we first examined in the MCF-7, HCC1937, and MDA-
MB-231cell lines NHEJ activity in vivo using a linearized plasmid
containing the luciferase reporter in the putative CIC containing
populations compared to the appropriate non CIC subsets. As
shown in Figure S2A, no increase of in vivo NHEJ was seen in
MCF-7 cells with the CD44
+/CD24
2or low phenotype compared
ATM Inhibitor Abolishes Radiation Resistance
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2/CD24
+. In contrast, increased in vivo NHEJ was
found in the CD44
2/CD24
high subset of HCC1937 and the
CD44
+/CD24
+ subset of MDA-MB-231 cells. However, the
increased in vivo NHEJ may merely reflect the low transfection
efficiency in the CD44
+/CD24
2 subsets of both cell lines as low
expression of the co-transfected reference gene, b-galactosidase,
was always noted. Further analysis of NHEJ function in vitro with
MDA-MB-231 cells showed that there was not a significant
difference in DNA ligation between CD44
+/CD24
2 and CD44
+/
CD24
+ subsets of MDA-MB-231 cells (Figure S2B). Combined
with post-radiation clonogenic survival results, the NHEJ analyses
suggest that enhanced clonogenic survival in CD44
+/CD24
2or low
subsets may not be a function of altered NHEJ activity.
4. Protein expression of DNA damage/repair response
genes after radiation in CD44
+/CD24
2or low
subpopulations
To further investigate the mechanisms of enhanced radiation
resistance in CD44
+/CD24
2or low subsets, we examined the
expression of DNA damage/repair related proteins before and
after radiation by western blot analysis (Figure S3 and Figure 5).
We first examined the expression of proteins responsible for NHEJ
and showed that Ku70, Ku 80, PARP, and DNA-PKcs were not
differentially expressed between CD44
+/CD24
2 and CD44
+/
CD24
+ MDA-MB-231 cells (Figure S3). These results supported
our observation that NHEJ did not contribute to enhanced
radiation resistance in the CD44
+/CD24
2 cell subset. However,
Figure 1. Post-radiation clonogenic survival and mammosphere formation analyses of the CD44
+/CD24
2or low subset vs. CD44
2/
CD24
high (MCF-7, Patient A, and Patient B) and CD44
+/CD24
+ (MDA-MB-231) subsets. A and B. As detailed in the Methods radiation dose-
response curves were performed either of unsorted MCF-7 cells (.) or the MCF-7 cell subsets CD44
+/CD24
2or low (&) and CD44
2/CD24
high (m) (Panel
A) or unsorted MDA-MB-231 cells (.), or the MDA-MB-231 cell subsets CD44
+/CD24
2 (&) or CD44
+/CD24
+ (m) (Panel B). Double open triangles
indicate a significant difference at the indicated dose of radiation with a P,0.01 between the CD44
+/CD24
2or low subset and the CD44
2/CD24
high
subset or unsorted cells for MCF-7 cells and between the CD44
+/CD24
2 subset and the CD44
+/CD24
+ subset or unsorted cells for MDA-MB-231 cells.
C. and D. Cells were cultured to form mammospheres from the CD44
+/CD24
2or low or the CD44
+/CD24
high subsets of Patient A (Panel C) and Patient B
(Panel D) as detailed in the Methods. In brief, the cells sorted from primary cultures were grown on low cell binding 96 well plates at a density of 200
cells in 0.2 ml of medium per well. The spheres formed were counted at day 12. The * indicates a significant difference with P,0.05 and ** indicates a
significant difference with P,0.01 between the CD44
+/CD24
2or low subset and CD44
2/CD24
highsubset. E and F. A radiation dose response curve was
performed on the CD44
+/CD24
2or low subset (&) and the CD44
+/CD24
+ subset (m) from Patient A (Panel E) and Patient B (Panel F) as detailed in the
Methods. Double open triangles indicate a significant difference at the indicated radiation dose with P,0.01 between the CD44
+/CD24
2or low subset
and the CD44
2/CD24
high subset in patient B cells.
doi:10.1371/journal.pone.0024080.g001
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that phosphorylated histone 2AX (c-H2AX), a marker of double
stranded DNA damage, was decreased by half in CD44
+/
CD24
2or low MCF-7 cells and ,three fold in CD44
+/CD24
2
MDA-MB-231 cells compared to the corresponding control
subsets one hour after radiation (Figure 5A). In the MDA-MB-
231 subset of CD44
+/CD24
2 cells, c-H2AX underwent faster
dephosphorylation than the CD24
+ subset with c-H2AX expres-
sion reduced by 75% in the CD44
+/CD24
2 subset 6 hours after
radiation while in CD44
+/CD24
+ subset expression of c-H2AX
did not change over time, suggesting delayed DNA repair in
CD44
+/CD24
+ cells.
H2AX is known to be phosphorylated by ATM and other
PIKK kinases [22]. In response to DNA damage, ATM is first
activated through auto-phosphorylation and by other kinases [23].
Hence, it was of interest to determine if ATM activation was
differentially affected in the CIC and non-CIC subsets following
radiation. In fact, one hour after radiation ATM phosphorylation
in the CD44
+/CD24
2or low subsets was significantly increased by
27% in MCF-7 cells compared to the corresponding control
subsets (Figure 5B, left panel). At 2 Gy, a level similar to a clinical
dose of radiation, the CD44
+/CD24
2 subset of MDA-MB-231
cells showed a seven fold increase of ATM phosphorylation
compared to the CD44
+/CD24
+subset (Figure 5B, right panel).
Interestingly, the ATM partner, ATR, was not differentially
phosphorylated in the two subsets before and after radiation
(Figure S4A). Expression of two other components of the DNA
damage-recognizing complex, MRE 11 and Nibrin, was similar
between the two subsets of MDA-MB-231 cells (Figure S4B). The
phosphorylation of ATM in the CD44
+/CD24
2 subset was
rapidly affected by radiation increasing by 85% 15 minutes after
radiation and was still increased by 40% after 60 minutes with far
smaller changes seen in the CD44
+/CD24
+ subset (Figure 5C).
Phosphorylation of the ATM target, BRCA1 also was slightly
increased by ,1.3 and 1.5 fold in the CD44
+/CD24
2 subset at 15
and 60 minutes compared to the CD44
+/CD24
+ subset
(Figure 5C) while there was no differential affect on p53
phosphorylation. In addition, we did not detect the expression of
phosphorylated checkpoint proteins, Chk1 and Chk2, under our
experimental conditions.
5. ATM inhibitor decreased the survival of the CD44+/
CD242 subpopulation after radiation
In view of the increased phosphorylation of ATM in the
CD44
+/CD24
2 subset in response to radiation and the important
function of activated ATM in the DNA repair process, we
hypothesized that differential activation of ATM was responsible
for increased radiation resistance in the CD44
+/CD24
2 subset.
To test this hypothesis, subsets of MDA-MB-231cells were treated
with KU55933 (2-Morpholin-4-yl-6-thianthren-1-yl-pyran-4-one),
an ATM kinase inhibitor, starting 2 hours before the radiation.
Western blot analysis showed a significant inhibition of ATM
phosphorylation 30 minutes after 10 Gy of radiation (Figure 6A).
Figure 2. CD44/CD24 expression after culture of sorted cells. MCF-7 (top panel) and MDA-MB-231 (bottom panel) cells were sorted by the
surface markers CD44 and CD24 as shown (column A) into CD44
+/CD24
2or low (3.0%) and CD44
2/CD24
high (3.2%) subsets for MCF-7 or CD44
+/CD24
2
(4.5%) and CD44
+/CD24
+ (4.5%) for MDA-MB-231. The parent cell lines (column B) and the subsets (columns C and D) were cultured for 20 days and
re-examined for CD44 and CD24 expression. The fluorescent intensity of CD 24 expression is on the Y axis and of CD44 expression on the X axis.
Shown is the percentage of cells in each quadrant.
doi:10.1371/journal.pone.0024080.g002
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that in the CD44
+/CD24
2 subset, cells treated with KU55933
were more sensitive to radiation than non-treated cells (Figure 6B).
The differential response of cells to radiation between the treated
and non-treated groups was especially significant at the lower
radiation doses. At 2Gy and 4Gy, the growth of cells treated with
the ATM inhibitor was reduced by 32% and 37%, respectively,
compared to growth of the non-treated cells. The analysis of
clonogenic survival showed that KU55933 decreased the survival
fraction by ten-fold in both CD44
+/CD24
2 and CD44
+/CD24
+
MDA-MB231 subsets (Figure 6C). Notably, treatment with
KU55933 attenuated the relative radiation resistance of CD44
+/
CD24
2subset compared to the CD44
+/CD24
+ subset with the
survival fractions after treatment with KU55933 being similar for
both subsets with no colonies detected for radiation greater than 2
Gy. In addition to the breast cancer cell line, KU55933 had a
similar effect on the two primary cultures of breast tumor, patients
A and B (Figure 6D and 6E). The western blot analyses of
phosphorylated ATM after radiation at 6Gy showed that the ratio
of phosphorylated ATM to total ATM which was 0.27 and 0.14 in
the untreated CD44
+/CD24
2/low and CD44
2/CD24
high subsets,
respectively, decreased to 0.04 and 0.04 in the KU55933 treated
CD44
+/CD24
2 and CD44
2/CD24
high subsets in patient B. In a
limited KU55933 dose response curve both the CD44
+/CD24
2
and CD44
+/CD24
+ subsets from the MDA-MB231 cells were
exquisitely sensitive with the survival fractions after 2 Gy
decreased by 12 fold by 2.5 mM KU55933 (Figure 7A). However,
the subsets from patient B cells were less sensitive with radiation
resistance being attenuated only at 10 mM KU55933 (Figure 7B).
These results suggest that the activation of ATM signaling could
be important for stem-like CIC survival and/or recovery post-
radiation. Inhibition of ATM could be an effective treatment to
attenuate the radiation resistance of the CIC of breast cancer.
Discussion
The presence of several surface markers has been utilized for the
isolation of stem-like CIC in breast cancer cell lines and tumor
tissue cells. Most notably, a subset of CD44
+/CD24
2/low cells
isolated from breast cancers appear enriched in CIC because of
the high potential tumorigenicity of these subsets. Other methods
to isolate CIC such as dye exclusion mediated by the membrane
transporter, ABCG2, or high expression of aldehyde dehydroge-
nase (ALDH) also appear to gate a subset of breast tumor cells
with the capacity to initiate tumors in a mouse model [24,25,26].
However, the CIC enriched cell subsets isolated by different
markers do not always overlap. For example, in our studies the
CD44
+/CD24
2 cells isolated from the MCF-7 breast cancer cell
Figure 3. The affect of culture on the radiation resistance of stem-like subsets. MCF-7 cells (Panels A and B) were sorted into CD44
+/
CD24
low (open bars) and CD44
2/CD24
high (solid bars) subsets. MDA-MB-231 cells (Panels C and D) were sorted into CD44
+/CD24
2 (open bars) and
CD44
+/CD24
+ (solid bars) subsets. A clonogenic survival analysis was conducted with calculation of the survival fraction at 2 Gy of radiation after 7
days (A and C), two weeks (B), or three weeks (D) of culture. Each column represents the mean of three independent experiments 6 SD. The single
and double stars represent a significant difference between two subsets in MCF7 and MDA-MB-231 cells with P,0.05 and P,0.01, respectively.
doi:10.1371/journal.pone.0024080.g003
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Hoechst 33342 excluding cells constituted 1.3% of the same
population.(data not shown) Likewise, in MDA-MB-231 cells,
CD44
+/CD24
2 cells were .85% of the cell population while
Hoechst 33342 excluding cells were less than 0.1% (data not
shown). The HCC38 cell line had neither cells with the CD44+/
CD242 phenotype nor any cells with the capacity to exclude the
Hoechst 33342 dye but 3.9% of cells expressed ALDH (data not
shown). Hence, while the CIC enriched subset may be isolated
from breast cancer cell lines by the CD markers CD44 and CD24,
ALDH, or membrane labeling dye PKH26 [14,24,27], obtaining
pure cancer stem cell subsets remains a challenge in methodology.
In the current studies, we utilized CD236/CD44/CD24 for
isolation of CIC of breast cancer cells based on previous studies
showing that ESA+/CD44
+/CD24
2or low breast cancer cell subset
from human breast cancer tissue and breast cancer cell lines is
more tumorigenic and more stem-like behavior. In addition,
CD44/CD24 has been applied as a criteria marker for
determining the stem-like CIC among breast cancer cell lines
treated with various factors to favor the growth of or transition to
stem-like cells. For example, mammosphere culture is used as a
method to verify the existence of stem-like cells with the stemness
of the resulting spheres being evaluated by CD44/CD24
expression [13]. Additionally, following a low dose of radiation
an increase in stem-like cells in the irradiated breast cancer cell
population was detected by flow cytometric analysis utilizing the
CD44/CD24 criteria for CIC [14]. The stemness of MCF-7 cells
with an active OCT4 promoter was also determined with CD44/
CD24 [28]. CD24
2/ESA
+ cells isolated from the MDA-MB-231
cell line showed accelerated growth of tumors in a xenograft model
and were also more radiation resistant [29]. With these examples
as precedent we assumed that selection of ESA
+/CD44
+/CD24
2
cells from breast cancer cell lines and from patient breast tissue
would be enriched in stem-like CIC. Our enhanced mammo-
sphere formation with patient breast cancer cells provided further
support for our assumption. In addition, clonogenic survival
analysis indicated that the populations enriched in CIC cells are
more radiation resistant than are the corresponding control
subsets, even in monolayer culture. The radiation resistance of the
CD44
+/CD24
2/low subset was not only exhibited in breast cancer
cell lines and primary culture of breast cancer cells but also in
benign tumor cells.
We were interested if the sorted subsets would maintain their
phenotype over time in culture or revert back to the pre-sort
equilibrium. Within the limits of two weeks of observation the
surface markers reverted back toward the presort pattern. That is,
the isolated CIC characterized by the CD44
+/CD24
2/low surface
phenotype proliferated in culture and after 14 days developed a
non-CIC phenotype. It was anticipated that the CIC would revert
back to the equilibrium condition that prevailed prior to the sort.
It is interesting, however, that the cells in the non-CIC subset
could not only renew themselves but also on subsequent sorts
could be seen to contain some cells with the stem-like CD44
+/
CD24
2 phenotype. This phenomenon is not caused by accidently
contamination. Because two sorting gates were not overlapped and
post-sorting demonstrated no contamination with each other.
Therefore, our observations challenge the stemness of isolated
stem-like CIC by raising two questions: 1) do the purported CIC
subsets really represent stem cells, and 2) does reversal of
differentiation exist in cancer cells? These two questions actually
bring us back to the long-lasting debate about the origin of cancer
and the stem cell versus de-differentiation theories [30]. The first
question is hotly debated but as CIC’s have tumorigenic potential
and therapeutic resistance while the non-CIC do not
[24,31,32,33], stem-like CIC’s seem to exist. As for the second
question, the mechanisms for the reversal of differentiation are not
currently understood. In the larger sense, cancer cells often exhibit
Figure 4. Analysis of radiation resistance of stem-like subsets
upon initial isolation and on the same subset obtained upon
resorting after culture. MCF7 cells (upper panel) were sorted into
CD44
+/CD24
low and CD44
2/CD24
high subsets and MDA-MB-231 cells
(lowerpanel)were sortedinto CD44
+/CD24
2 andCD44
+/CD 24
+ subsets.
All four subsets were cultured for 20 days, resorted into the same subsets
and clonogenic survival analyses were performed after radiation with
either 2 Gy (2) or 4 Gy (4). Shown are the means 6 SD of 3 experiments.
Statistical analyses were performed with two-way ANOVA analysis. The
stars indicate a significant difference with P,0.01 in the survival fraction
of the resorted CIC group compared to the resorted non CIC groups. In
upper panel CD44
+/CD24
low and CD44
2/CD24
high mean 20 day cultured
MCF7 subsets. CD44
+/CD24
low to CD44
+/CD24
low and CD44
+/CD24
low to
CD44
2/CD24
high indicate that cells were re-sorted into CD44
+/CD24
low
and CD44
2/CD24
high subsets from 20 day cultured CD44
+/CD24
low
subset. CD44
2/CD24
high to CD44
+/CD24
lowand CD44
2/CD24
high to
CD44
2/CD24
high indicate that cells were re-sorted into CD44
+/CD24
low
and CD44
2/CD24
high subsets from 20 day cultured CD44
2/CD24
high
subset. In lower panel CD44
+/CD24
2 and CD44
+/CD24
+ mean 20 day
cultured MDA-MB-231 subsets. CD44
+/CD24
2 to CD44
+/CD24
2 and
CD44
+/CD24
2 to CD44
+/CD24
+ indicate that cells were re-sorted into
CD44
+/CD24
2 and CD44
+/CD24
+ subsets from 20 day cultured CD44
+/
CD24
2 subset. CD44
+/CD24
+ to CD44
+/CD24
2and CD44
+/CD24
+ to
CD44
+/CD24
+ indicate that cells were re-sorted into CD44
+/CD24
2 and
CD44
+/CD24
+ subsets from 20 day cultured CD44
+/CD24
+ subset.
doi:10.1371/journal.pone.0024080.g004
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24080reversed differentiation expressing proteins usually expressed in the
embryonic phase of normal tissue development. In addition, genetic
instability of cancer cells could provide a mechanism for reversal of
differentiation. The phenomenon of reversal of differentiation was
not only exhibited with the altered expression of CD44/CD24
surface markers during culture but was also noticed in altered
expression of ABCG2 in breast cancer cells [34]. Most importantly,
in our studies as an example of reversal of differentiation, is that
radiation resistance appears to be directly related to the surface
phenotype and after two or three weeks of culture with the CD44
+/
CD24
2 phenotype reverting to the CD44
2/CD24
+ phenotype
radiationsensitivitywas restored (Figure 3).A recent reportindicates
that epithelial cells can generate cells with properties of stem cells
through epithelial-mesenchymal transition [35] suggesting that non
stem-like cancer cells may become stem-like cells through de-
differentiation or reprogramming and through the epithelial-
mesenchymal transition.
The reasons for enhanced radiation resistance of CIC are not
completely understood. The therapeutic effect of radiation on
cancer cells is partially mediated by free radicals and hence by the
production of reactive oxygen species (ROS). The basal ROS level
is lower in CIC than that in non-CIC and the CIC also have
enhanced antioxidant defenses with maneuvers which increased
ROS levels also restoring radiation sensitivity [15]. In addition to
the balance between ROS production and antioxidant systems,
other factors that may contribute to CIC radiation resistance
include the ability to repair radiation-mediated cell damage.[18]
The repair of radiation induced double strand DNA breaks is
Figure 5. The differential response to radiation correlates with differential phosphorylation of ATM and its downstream targets
between CD44
+/CD24
2 and CD44
+/CD24
+ subsets in MDA-MB231 cells and between CD44
+/CD24
low and CD44
2/CD24
high subsets
in MCF-7 cells. The indicated sorted subsets of MCF-7 and MDA-MB231 cells were cultured for 5 days as described in the Methods and radiated with
the indicated doses. Whole cell extracts (MCF-7) or nuclear extracts (MDA-MB-231) were analyzed by western blot analysis for the presence of
phosphorylated cH2AX (A), phosphorylated ATM (B), and BRCA1 and p53 (C) the downstream targets of phosphorylated ATM. between CD44
+/
CD24
2 and CD44
+/CD24
+ subsets of MDA-MB231 cells. In C western blot analyses were conducted for time-related changes in phosphorylated ATM,
phosphorylated BRCA1, and phosphorylated p53. The ATR expression was utilized as a loading control.
doi:10.1371/journal.pone.0024080.g005
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homologous recombination (HR). We found no differences in the
NHEJ activity in the CD44
+/CD24
2 and non CD44
+/CD24
2
subsets nor were there any significant differences following
radiation. While we did not directly measure the HR activity in
the CD44
+/CD24
2 and non CD44
+/CD24
2 subsets we did
examine the activation of Ataxia-Telangiectasia Mutated Kinase
(ATM), which is an initiating factor for HR, and found that the
Figure 6. The ATM inhibitor KU55933 decreases the radiation resistance of stem-like MDA-MB-231, Patient A, and Patient B cells.
Cells sorted and cultured as in Figure 1 were treated with ATM inhibitor KU55933. A. Western blot analysis of phosphorylated ATM 30 minutes after
radiation at 10Gy in MDA-MB-231 cells treated with 20 mM of the ATM inhibitor KU55933 for two hours before radiation. B. The proliferation analysis
of ATM inhibitor treated cells. MDA-MB-231 cells were treated with the 20 mM of KU55933 from two hours before radiation to 24 hour after radiation
and cell numbers enumerated as described in the Methods after 7 days in culture. The results are expressed as the percent of cells compared to the
non-radiated control and represent the mean 6 SD of three independent experiments. The solid squares represent the CD44
+/CD24
2 subset, the
triangles, the CD44
+/CD24
+ subset. Single and double open triangles indicate a significant difference with P,0.05 and 0.01 between KU55933 treated
and untreated CD44
+/CD24
2 subset of MDA-MB-231 cells. C, D, and E. The clonogenic survival analysis of the CD44
+/CD24
2 subset vs. CD44
+/CD24
+
subset in MDA-MB-231 cells (C) and CD44
+/CD24
2or low subset vs CD44
2/CD24
high subset in Patient A (D) and Patient B cells (E). Sorted cells were
treated with 10 mM of KU55933 one hour before the radiation and then irradiated as described in Materials and Methods. 48 hour after radiation,
medium was replaced with fresh medium without KU55933. The colonies were counted at day 12. The solid square represents the CD44
+/CD24
2
subset in C and CD44
+/CD24
2or low subset in D and E. The m triangle represents the CD44
+/CD24
+ subset in C and the CD44
2/CD24
high subset in D
and E. The . triangle represents the KU55933 treated CD44
+/CD24
2 subset in C and CD44
+/CD24
2or low subset in D and E. The ¤ represents KU55933
treated CD44
+/CD24
+ subset in C and CD44
2/CD24
high subset in D and E. Double open triangles indicate a significant difference at 2Gy with P,0.01
between KU55933 treated and untreated CD44
+/CD24
2 subsets in C and between the KU55933 treated and untreated CD44
+/CD24
2or low subset in
E. F. Western blot analysis of phosphorylated ATM 60 minutes after radiation at 6 Gy in Patient B cells treated with 10 mM of the ATM inhibitor
KU55933 for one hour prior to radiation.
doi:10.1371/journal.pone.0024080.g006
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+/CD24
2 subset as was
BRCA1 which is a down-stream target of ATM. The enhanced
activation of ATM in CD44
+/CD24
2 subset was manifest both as
increased phosphorylation of ATM and also as delayed dephos-
phorylation. In contrast, phosphorylated c-H2AX, a marker of
DNA double strand breaks and a protein which is phosphorylated
by ATM, was not increased in CD44
+/CD24
2 subset compared
to non CD44
+/CD24
2 subset and the phosphorylated levels of c-
H2AX subsided more quickly in the CD44
+/CD24
2 subset than
the non CD44
+/CD24
2 subset. Perhaps, in CIC the persistence of
phosphorylated ATM and the rapid decrease of phosphorylated c-
H2AX allow for more rapid DNA repair and hence enhanced cell
survival.
ATM is a Ser/Thr kinase and belongs to phosphatidylinositol 39
kinase-related kinase family. The functions of ATM have been
well reviewed [36,37]. ATM participates in multiple stress-related
activities and plays a critical role in the maintenance of genome
stability and integrity with mutations of ATM closely related to
cancer predisposition including breast cancer. In response to
double strand DNA damage, ATM is activated through auto-
phosphorylation at several residues including Ser1981 and by
poly(ADP-ribosyl)ation by PARP protein [38]. Activated ATM
can initiate homologous recombination repair by phosphorylating
a series of substrate proteins. Activated downstream targets of
ATM/ATR after radiation may consist of over 900 proteins
[39].The In glioblastomas and atypical teratoid/rhabdoid tumors,
stem cells characterized by the CD133
+ phenotype demonstrated
increased radiation resistance accompanied by enhanced expres-
sion of phosphorylated ATM and the checkpoint proteins Chk1,
Chk2, and Rad17 compared to CD133
2 cells [16,17]. The
checkpoint kinase inhibitor debromohymenialdisine (DBH) effec-
tively eliminated the radiation resistance of the CD133
+ cells [32].
In our studies both the breast cancer cell lines MDA-M-231 and
MCF-7 and the primary culture of patient breast cancer cells
demonstrated enhanced expression of phosphorylated ATM in the
CD44
+/CD24
2or low subpopulation after radiation. In contrast to
the findings with CD133
+ positive cells from brain tumors, only
slightly increased activation of downstream pathways was found
primarily in BRCA1 although additional downstream targets of
ATM in breast cancer CIC need to be examined.
Recently, ATM inhibitors were demonstrated to enhance
radiation sensitivity of cancer cells and suppression of the
proliferation of tumor cells [40,41,42]. In an initial study we used
the ATM inhibitor KU-55933 [43] and showed significantly
decreased radiation resistance of the CD44
+/CD24
2 subset
isolated both from of the MDA-MB-231 cell line and the primary
culture of patient breast cancer cells. These results suggest that
ATM signaling could be an important target for radiation
resistance of CIC and development of new therapeutic strategies
aimed at ATM may provide a way to extinguish CIC in breast
cancer.
Materials and Methods
Cell culture, antibodies, and reagents
The breast cancer cells lines, MCF7and MDA-MB-231, MDA-
MB-436, BD20, HCC38, and HCC1937 were purchased from
ATCC and cultured according to the ATCC instructions. The
primary breast cells were collected from patients under the
exempted protocol (Protocol Number: E09-032) approved by the
Institutional Review Board for Human Research Subjects of
Louisiana State University Health Sciences Center-Shreveport.
No patient can be identified. Briefly, the breast tissues were
disassociated with collagenase I (Invitrogen, Carlsbad, CA) at 200
unit/ml at 37Cu overnight. After centrifugation and washing, the
isolated small organoids and cells were cultured on Primaria Plates
(Becton Dickinson, Franklin Lakes, NJ) in WIT medium
(Stemgent, Cambridge, MA). In some cases, the medium was
supplemented with 2% FBS to promote the growth of breast
epithelial cells. The isolated breast cells were used within five to six
passages. Antibodies (with catalogue numbers in parentheses) for
use in western blot analysis were obtained from: 1) Cell Signaling
Technology, Inc. (Danvers, MA) against phosphorylated ATM
(#4526), phosphorylated ATR (#2853), phosphorylated P53
(#9286), phosphorylated BRCA1 (#9009), or phosphorylated
histone 2A.X (#9718); 2) Lab Vision (Fremont, CA) against Ku70
(#MS-329), Ku80 (#MS-332), and DNA-PK (#MS-370); and 3)
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) against Rad50
(sc-20155), MRE11 (sc-5898), Nibrin (sc-8580), Ku86 (sc56136),
ATM (sc-23921), ATR (sc-28901), and PARP1(sc-8007). ATM
inhibitor KU55933 was purchased from Tocris (Ellisville, MO)
and dissolved in DMSO at 10 mM.
Figure 7. Dose-effect relationship of KU55933 and clonogenic
survival fraction in MDA-MB-231 and Patient B cells. Sorted
MDA-MB-231 (A) and patient B (B) cells were treated with various
concentrations of KU55933 as indicated for one hour before the
radiation and then irradiated at 2Gy. The colonies were enumerated as
in Figure 6 and the survival fractions were calculated The open bar
represents the CD44
+/CD24
2 subset in A and the CD44
+/CD24
2or low
subset in B. The solid bar represents the CD44
+/CD24
+ subset in A and
CD44
2/CD24
high subset in B.
doi:10.1371/journal.pone.0024080.g007
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Cells were trypsinized and suspended in PBS plus 1% fetal
bovine serum at a density of 1610
7 cells/ml. Antibodies against
CD44 (# 555478, BD Pharmingen, San Jose, CA), CD24
(#555428, BD Pharmingen) or epithelium marker CD326 (ESA)
(#234208, BioLegend, San Diego, CA) were added at dilutions of
1:10 to 1:20 as suggested by the manufacturer and incubated on
ice for 40 minutes. After washing with PBS containing 1% fetal
bovine serum, the labeled cells were first gated to CD326 and then
the CD326 positive cells were sorted by CD44 and CD24 markers
on a FACSVantage Flow Cytometer/Cell Sorter. The sorted
subsets of cells were cultured for 5–6 days.
Radiation, cell proliferation and clonogenic survival
assays
2610
5 cells suspended in 2 ml of complete medium in 15 ml
plastic tubes were exposed at room temperature to radiation at
doses ranging 2 to 8 Gy from a Cesium-137 irradiator. For
proliferation assays after exposure to radiation, cells were grown in
96-well plates at initial densities of about 5,000 cells/well in
complete culture medium containing 10% FBS. The cell
proliferation assay was conducted 5 days after radiation exposure
with the CellTiter 96H AQueous Non-Radioactive Cell Prolifera-
tion Assay Kit (Promega, Madison, WI) according to the
manufacturer’s instruction. For the clonogenic survival assay,
radiated cells were plated at densities of 300 to 3000 cells per well
in 6-well plates depending on the radiation dose. After 10 days the
cells were stained with 0.05% crystal violet and the colony number
enumerated by light microscopy.
Non-homologous end joining assay (NHEJ)
The NHEJ assay was conducted according to our previous work
[14]. Briefly, nuclear extracts were prepared within one hour after
radiation with NE-PERH nuclear extraction reagents and 20–
25 mg of nuclear protein was mixed with 400 ng of BamH1 and
Xho1 digested pBlueKs plasmid DNA in 50 mM Tris-HCL
pH 8.0, 40 mM KOAc, 0.5 mM EDTA, 1 mM ATP, 1 mM
DTT, 200 mM dNTPs, 100 mg/ml bovine serum albumin, and
varying concentrations of magnesium in a total volume of 50 ml.
Following incubation at 37uC for 2 hours, the reaction mixture
was treated with protease K and extracted with phenol/
chloroform. One half of each reaction was separated on a 0.8%
agarose gel and stained with Gelstar (Cambrex Corporation, East
Rutherford, NJ). The stained gels were scanned and the
percentage of end rejoining was calculated by dividing the sum
of dimers and multimers by the sum of monomers, dimers, and
multimers.
In vivo ligation assay
The luciferase reporter pGL2 control plasmid (Promega) was
linearized with Sma 1 and linearization verified by agarose
electrophoresis. Cells with or without radiation were transfected
with linearized pGL2 and beta-gal plasmids with Lipofectamine
2000. After 36 hour, cells were lysed and luciferase activity was
measured and standardized by beta-Galactosidase activity.
Evaluation of sphere formation
Single cell suspensions of sorted patient breast cancer cells or
cell lines were grown in 96-well low cell binding plates at a density
of 200 cells in 200 ml of Dulbecco’s modified Eagle’s medium/F-
12 containing 5 mg/mL insulin, 0.5 mg/mL hydrocortisone1x
B27 (Invitrogen, Carlsbad, CA), 20 ng/ml epidermal growth
factor, and 20 ng/ml basic fibroblast growth factor. After 12 days,
the numbers of formed spheres per well were counted by
microscopy.
Western blot analysis
Nuclear proteins were extracted with NE-PER (Pierce Biotech-
nology, Rockford, IL). Whole cell extracts were prepared either
with RIPA buffer (PBS, 1% Nonidet P-40 (NP-40), 0.25% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS)) containing 16
protease inhibitor cocktail (Roche Applied Science, Indianapolis,
IN) or with Laemmli sample buffer. Protein concentrations were
determined by the BCA Protein Assay Kit (Pierce Biotechnology).
Both nuclear and whole cell proteins were separated by
electrophoresis on SDS-PAGE, transferred to Hybond
TM ECL
nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ),
and blocked with 5% non-fat milk in 16 TBST (10 mM Tris-
HCL, pH 8.0; 150 mM NaCl; 0.05% Tween-20). The blots were
then incubated with the indicated antibodies at 4uC overnight,
washed, incubated with peroxidase-conjugated secondary anti-
bodies, and signals detected with SuperSignal Dura or Pico
Substrate (Pierce Protein Research Products, Rockford, IL).
Supporting Information
Figure S1 Flow cytometric analysis of CD44 and CD24.
Cells from the cell lines MCF-7 (A) and MDA-MB-231 (B) and
from primary culture of Patient A (C) and Patient B (D) were
stained with APC-conjugated CD326 (ESA), FITC-conjugated
CD44, and PE-conjugated CD24 and analyzed by flow cytometry
as detailed in the Methods. The percentage of CD326 positive cells
is shown in the upper right corner of each panel in the left column.
The CD326 (ESA) positive cells were then analyzed for CD44 and
CD24 (left panel) with the percentage of cells that were CD44
+/
CD24
2 (i.e. quadrant 4) presented in the Results. The CD326+/
CD44
+/CD24
2or low subsets (P6) and control subsets (P5) were
sorted according to the gates as shown in each panel of the right
column.
(EPS)
Figure S2 Analysis of DNA ligation activity among
subsets of MCF-7, HCC1937, and MDA-MB-231 cell
lines. A. In vivo analysis of DNA ligation activity among
subpopulations of MCF-7, HCC1937, and MDA-MB-231 cell
lines. The pGL2-Control plasmid with the SV40 promoter driven
luciferase reporter gene was linearized by Stu1 to create blunt ends
between promoter and luciferase reporter gene. The linearized
plasmid was transfected into subpopulations of MCF-7, HCC193,
and MDA-MB-231 cells prior to and post radiation. The luciferase
activity was measured 36 hours after transfection. The luciferase
activity was standardized by b-gal activity for transfection
efficiency and the data presented as relative light units. B. NHEJ
analysis of DNA ligation activity between CD44
+/CD24
2 and
CD44
+/CD24
+ subsets. Sorted MDA-MB231 cells were radiated
and nuclear protein was extracted. The analysis of NHEJ activity
was conducted with plasmid DNA pBlue ks linearized with
BamH1 and Xho1 in the absence or presence of varying
concentrations of MgCl2.
(EPS)
Figure S3 Western analysis of expression of Ku70,
Ku80, PARP1, and DNA-PKcs among the sorted subsets
of cells. A. MDA-MB-231 cells were sorted into CD44
+/CD24
2
and CD44
+/CD24
+ subsets and HCC1937 cells were sorted into
CD44
+/CD24
low and CD44
2/CD24
high subsets. The subpopula-
tions were radiated as indicated and nuclear extracts were
prepared as detailed in the Methods and subjected to western
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24080blot analysis to detect KU-70/80 and PARP1. B. Western analysis
of expression of DNA-PKc in sorted MDA-MB-231 cells. C.
Western analysis of DNA-PKc in sorted MCF-7 cell.
(EPS)
Figure S4 Western analysis of expression of phosphor-
ylated ATR and the Mre11 and Nibrin. components of the
DNA damage recognizing complex. Western analyses were conduct-
ed asin Figure 5. Expressionof phosphorylated ATR in sorted MDA-
MB-231 cells is shown in A and the expression of Mre11 and Nibrin
in sorted MDA-MB-231 and MCF-7 cells is shown in B.
(EPS)
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